[{"address1": "4275 Executive Square", "address2": "Suite 950", "city": "La Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "858-789-9283", "website": "https://www.longboardpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.", "fullTimeEmployees": 50, "companyOfficers": [{"maxAge": 1, "name": "Mr. Kevin R. Lind", "age": 47, "title": "President, CEO, Secretary & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1066870, "exercisedValue": 0, "unexercisedValue": 1291593}, {"maxAge": 1, "name": "Ms. Brandi L. Roberts CPA, M.B.A.", "age": 49, "title": "Executive VP & CFO", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 662653, "exercisedValue": 0, "unexercisedValue": 117382}, {"maxAge": 1, "name": "Dr. Randall E. Kaye M.D.", "age": 61, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 717954, "exercisedValue": 0, "unexercisedValue": 53915}, {"maxAge": 1, "name": "Mr. Chadwick J. Orevillo MPH", "title": "Executive VP & Head of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan E. Knight", "title": "VP & Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steven W. Spector J.D.", "age": 58, "title": "Executive VP, Head of Business Development & General Counsel", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Anne M. Danks Ph.D.", "title": "VP & Head of Nonclinical Research & Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gus  Cardenas", "title": "VP & Head of Quality Assurance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marco  Peters Ph.D.", "title": "VP & Head of Translational Science", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dewey  McLin Ph.D.", "title": "VP & Head of Medical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 35.82, "open": 36.28, "dayLow": 35.69, "dayHigh": 38.1099, "regularMarketPreviousClose": 35.82, "regularMarketOpen": 36.28, "regularMarketDayLow": 35.69, "regularMarketDayHigh": 38.1099, "beta": 1.259, "forwardPE": -16.120691, "volume": 588232, "regularMarketVolume": 588232, "averageVolume": 537921, "averageVolume10days": 727280, "averageDailyVolume10Day": 727280, "bid": 37.28, "ask": 37.43, "bidSize": 200, "askSize": 200, "marketCap": 1454115840, "fiftyTwoWeekLow": 3.6, "fiftyTwoWeekHigh": 40.48, "fiftyDayAverage": 25.6391, "twoHundredDayAverage": 17.64335, "currency": "USD", "enterpriseValue": 1137053056, "floatShares": 23677953, "sharesOutstanding": 33609300, "sharesShort": 4466915, "sharesShortPriorMonth": 4112771, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.1149, "heldPercentInsiders": 0.0109, "heldPercentInstitutions": 1.1886001, "shortRatio": 4.96, "shortPercentOfFloat": 0.15529999, "bookValue": 8.069, "priceToBook": 4.635023, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -57952000, "trailingEps": -2.25, "forwardEps": -2.32, "enterpriseToEbitda": -18.077, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "LBPH", "underlyingSymbol": "LBPH", "shortName": "Longboard Pharmaceuticals, Inc.", "longName": "Longboard Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1615559400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3613b707-ae0b-3b49-aa53-370148927a51", "gmtOffSetMilliseconds": -14400000, "currentPrice": 37.4, "targetHighPrice": 90.0, "targetLowPrice": 32.0, "targetMeanPrice": 53.33, "targetMedianPrice": 45.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 321043008, "totalCashPerShare": 8.257, "ebitda": -62902000, "totalDebt": 3982000, "quickRatio": 31.2, "currentRatio": 31.433, "debtToEquity": 1.269, "returnOnAssets": -0.19304001, "returnOnEquity": -0.30039, "freeCashflow": -31462876, "operatingCashflow": -52948000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-29"}]